Terms: = Ovarian cancer AND TRIM27, DASS-46L4_6, RFP, 5987, ENSG00000234495, RNF76 AND Treatment
7303 results:
1. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
[TBL] [Abstract] [Full Text] [Related]
2. Advances in precision therapy of low-grade serous ovarian cancer: A review.
Wang Q; Cao SH; Li YY; Zhang JB; Yang XH; Zhang B
Medicine (Baltimore); 2024 Apr; 103(17):e34306. PubMed ID: 38669365
[TBL] [Abstract] [Full Text] [Related]
3. Granulosa cell tumor of the ovary: a series of 6 cases.
da Costa REAR; Silva MCA; Cavalcante ECX; Branco ROC; Dos Reis CA; Vieira SC
Pan Afr Med J; 2024; 47():58. PubMed ID: 38646138
[TBL] [Abstract] [Full Text] [Related]
4. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
[TBL] [Abstract] [Full Text] [Related]
5. Effect of different treatment modalities on ovarian cancer patients with liver metastases: A retrospective cohort study based on SEER.
Li N; Jin S; Wu J; Ji H; Du C; Liu B
PLoS One; 2024; 19(4):e0299504. PubMed ID: 38635517
[TBL] [Abstract] [Full Text] [Related]
6. A Study on the Retrospective Reinterpretation of BRCA1 and BRCA2 Variants.
Kim JJ; Kim DJ; Nam EJ; Song KE; Ham JY; Kim YK; Lee NY
Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623660
[TBL] [Abstract] [Full Text] [Related]
7. The Predictive Role of Serum Lipid Levels, p53 and ki-67, According to Molecular Subtypes in Breast cancer: A Randomized Clinical Study.
Faur IF; Dobrescu A; Clim IA; Pasca P; Prodan-Barbulescu C; Tarta C; Neamtu AA; Brebu D; Neamtu C; Rosu M; Duta C; Clim A; Lazar G; Totolici B
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612725
[TBL] [Abstract] [Full Text] [Related]
8. Common misconceptions and myths about ovarian cancer causation: a national cross-sectional study from palestine.
Elshami M; Jaber I; Alser M; Al-Slaibi I; Jabr H; Ubaiat S; Tuffaha A; Khader S; Khraishi R; Arafeh ZA; Al-Madhoun S; Alqattaa A; Yaseen A; El Hadi AA; Barhoush O; Hijazy M; Eleyan T; Alser A; Hziema AA; Shatat A; Almakhtoob F; Mohamad B; Farhat W; Abuamra Y; Mousa H; Adawi R; Musallam A; Albarqi SI; Abu-El-Noor N; Bottcher B
BMC Public Health; 2024 Apr; 24(1):1027. PubMed ID: 38609950
[TBL] [Abstract] [Full Text] [Related]
9. Olaparib Addition to Maintenance Bevacizumab Therapy in ovarian Carcinoma With BRCA-Like Genomic Aberrations.
Schouten PC; Schmidt S; Becker K; Thiele H; Nürnberg P; Richters L; Ernst C; Treilleux I; Medioni J; Heitz F; Pisano C; Garcia Y; Petru E; Hietanen S; Colombo N; Vergote I; Nagao S; Linn SC; Pujade-Lauraine E; Ray-Coquard I; Harter P; Hahnen E; Schmutzler RK
JAMA Netw Open; 2024 Apr; 7(4):e245552. PubMed ID: 38592722
[TBL] [Abstract] [Full Text] [Related]
10. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Kim YN; Chung YS; Park E; Lee ST; Lee JY
Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
[TBL] [Abstract] [Full Text] [Related]
11. Tumor-Infiltrating Lymphocytes in Triple-Negative Breast cancer.
Leon-Ferre RA; Jonas SF; Salgado R; Loi S; de Jong V; Carter JM; Nielsen TO; Leung S; Riaz N; Chia S; Jules-Clément G; Curigliano G; Criscitiello C; Cockenpot V; Lambertini M; Suman VJ; Linderholm B; Martens JWM; van Deurzen CHM; Timmermans AM; Shimoi T; Yazaki S; Yoshida M; Kim SB; Lee HJ; Dieci MV; Bataillon G; Vincent-Salomon A; André F; Kok M; Linn SC; Goetz MP; Michiels S;
JAMA; 2024 Apr; 331(13):1135-1144. PubMed ID: 38563834
[TBL] [Abstract] [Full Text] [Related]
12. Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patients.
Yuan H; Li N; Wu L; Yao H
J Ovarian Res; 2024 Apr; 17(1):70. PubMed ID: 38561819
[TBL] [Abstract] [Full Text] [Related]
13. The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial.
Giudice E; Huang TT; Nair JR; Zurcher G; McCoy A; Nousome D; Radke MR; Swisher EM; Lipkowitz S; Ibanez K; Donohue D; Malys T; Lee MJ; Redd B; Levy E; Rastogi S; Sato N; Trepel JB; Lee JM
Nat Commun; 2024 Mar; 15(1):2805. PubMed ID: 38555285
[TBL] [Abstract] [Full Text] [Related]
14. Characteristics of patients with late recurrence endometrial cancer.
Çakır İ; Gülseren V; Özdemir İA; Abacı H; Talu ECK; Çakır ZE; Ata C; Kuru O; Gökçü M; Sancı M; Güngördük K
J Cancer Res Ther; 2024 Jan; 20(1):232-237. PubMed ID: 38554326
[TBL] [Abstract] [Full Text] [Related]
15. Podocalyxin promotes the formation of compact and chemoresistant cancer spheroids in high grade serous carcinoma.
Le Tran N; Wang Y; Bilandzic M; Stephens A; Nie G
Sci Rep; 2024 Mar; 14(1):7539. PubMed ID: 38553472
[TBL] [Abstract] [Full Text] [Related]
16. Comparison of the multiples of the median of serum anti-müllerian hormone and pregnancy outcomes in patients with gestational trophoblastic disease: A case-control study.
Lai THT; Lau LSK; Ngu SF; Chu MYM; Chan KKL; Ng EHY; Ngan HYS; Li RHW; Tse KY
Cancer Med; 2024 Apr; 13(7):e7134. PubMed ID: 38545760
[TBL] [Abstract] [Full Text] [Related]
17. [Clinical analysis of 12 cases of ovarian yolk sac tumor].
Liu J; Chu HJ; Shan YP; Song WJ; Chen AP
Zhonghua Fu Chan Ke Za Zhi; 2024 Mar; 59(3):210-214. PubMed ID: 38544450
[No Abstract] [Full Text] [Related]
18. Noscapine and Apoptosis in Breast and Other cancers.
Calaf GM; Crispin LA; Quisbert-Valenzuela EO
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542508
[TBL] [Abstract] [Full Text] [Related]
19. A Survival Analysis of Patients with Recurrent Epithelial ovarian cancer Based on Relapse Type: A Multi-Institutional Retrospective Study in Armenia.
Harutyunyan L; Manvelyan E; Karapetyan N; Bardakhchyan S; Jilavyan A; Tamamyan G; Avagyan A; Safaryan L; Zohrabyan D; Movsisyan N; Avinyan A; Galoyan A; Sargsyan M; Harutyunyan M; Nersoyan H; Stepanyan A; Galstyan A; Danielyan S; Muradyan A; Jilavyan G
Curr Oncol; 2024 Mar; 31(3):1323-1334. PubMed ID: 38534933
[TBL] [Abstract] [Full Text] [Related]
20. Patient-reported outcome measures (PROMs) to personalise follow-up care of ovarian cancer: what do patients think? A qualitative interview study.
Seeratan DD; van Schuylenburch RG; van Lonkhuijzen LRCW; Aarts JWM
Support Care Cancer; 2024 Mar; 32(4):247. PubMed ID: 38528152
[TBL] [Abstract] [Full Text] [Related]
[Next]
